Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose of hydroxychloroquine when given together with
binimetinib in treating patients with KRAS gene mutated pancreatic cancer that has spread to
other places in the body (metastatic). Binimetinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Hydroxychloroquine may prevent
autophagy, a normal process in which a cell destroys proteins and other substances which may
lead to cell death. Autophagy may prevent normal cells from developing into tumor cells, but
it may also protect tumor cells by destroying anticancer drugs or substances taken up by
them. Giving hydroxychloroquine together with binimetinib may work better in treating
patients with pancreatic cancer compared to binimetinib alone.